This is an automatically translated article.
Tenfova medicine has the main ingredients Tenofovir disoproxil fumarate 300mg and Emtrricitabin 200mg. The drug is used to treat HIV infection. Here is some useful information about Tenfova to help patients learn to use it safely and effectively.
1. What is Tenfova?
Drug Tenfova is a drug belonging to the group of drugs used to treat parasites, anti-infectives, antivirals, antifungals. Tenfova is prepared in the form of film-coated tablets and is packaged in boxes of 3 blisters x 10 tablets.
Tenfova drug has the main ingredients Tenofovir disoproxil fumarate and Emtrricitabine along with some other excipients, just enough for 1 tablet.
2. What are the effects of Tenfova?
Tenfova is indicated for fixed-dose use in the case of combined oral therapy with antiretrovirals for adults with HIV-1 infection.
There have been studies confirming the benefit of the combination drug Emtricitabine and Tenofovir disoproxil fumarate in antiretroviral therapy, performed in previously untreated patients.
Patients need to adhere to the use of drugs in accordance with the indications on the use and function of the drug for each subject.
3. Dosage - How to take Tenfova
3.1. How to use Tenfova is prepared in the form of film-coated tablets and is used by mouth, according to tablets.
3.2. Dosage Tenfova drug dose depends on each subject and the course of the disease, there will be an appropriate dose. Here is the dose of Tenfova for reference as follows:
Patients must use the drug exactly under the guidance of the examining doctor or pharmacist. Patients need to start taking medication as prescribed by a doctor experienced in the treatment of HIV infection. For adults: The recommended dose when using Tenfova is one tablet, once a day. The drug should be taken in combination with food to maximize the absorption of tenofovir from the combination tablet. For the elderly: No dosage adjustment is necessary for patients > 65 years of age, unless the patient has renal impairment. Because, there are still insufficient data to make dosing recommendations for patients > 65 years of age.
4. What to do when using an overdose of Tenfova?
In the case of an overdose of Tenfova, the symptoms of overdose have not been recorded. If the patient uses an overdose, it is necessary to monitor for signs of toxicity. In case of necessity, basic supportive measures should be used. Tenofovir is effectively eliminated by hemodialysis with a separation coefficient of approximately 54%. With a single 300 mg dose of Tenofovir, approximately 10% of a tenofovir disoproxil fumarate dose was eliminated during a long 4-hour hemodialysis session.
5. Contraindications of the drug Tenfova
Tenfova drug should not be used in patients with hypersensitivity or history of allergy to Emtricitabine, Tenofovir disoproxil fumarate or to any of the ingredients in the drug.
6. Tenfova drug interactions
The following are some of the reported Tenfova drug interactions such as:
When Tenfova is used together with other drugs, the drugs will be affected or metabolized by liver enzymes: Due to interaction pharmacokinetic properties of Tenofovir with inhibitors or substrates of unknown liver enzymes. Tenofovir and its prodrugs, which are not CYP450 substrates, do not inhibit the CYP isoforms 3A4, 2D6, 2C9, or 2E1 but are slightly above 1A. Drugs that are affected or eliminated by the kidneys when used in combination with Tenfova: Tenfova interacts with drugs that reduce kidney function and compete for renal excretion such as the following drugs: Acyclovir, Cidofovir, Ganciclovir, Valacyclovir, Valganciclovir. Such co-administration will result in increased plasma concentrations of tenofovir or co-administered drugs. When using Tenfova with HIV Proteaz Inhibitors: Some HIV Proteaz Inhibitors such as Amprenavir, Atazanavir, Indinavir, Ritonavir, Saquinavir. When combined with the drug Tenfova will cause additive or synergistic interactions between tenofovir and other substances. Interaction between Tenfova and non-Nucleoside reverse transcriptase inhibitors: Drugs that interact with synergistic or synergistic interactions between Tenofovir and non-Nucleoside reverse transcriptase inhibitors such as: Delavirdin, Efavirenz, Nevirapin. Interaction between Tenfova and Nucleoside reverse transcriptase inhibitors: Drugs that interact synergistically or synergistically between Tenofovir and Nucleoside reverse transcriptase inhibitors such as Abacavir, Didanosin, Emtricitabin, Lamivudin , Stavudin, Zalcitabine, Zidovudine. Interactions of Tenfova with Oral Contraceptives: For oral contraceptives containing ethinyl estradiol and norgestimate, the pharmacokinetic interactions with Tenofovir are unknown.
7. Tenfova . side effects
In the process of using Tenfova, patients may experience some unwanted side effects such as:
Most common effects:
There are mild effects on the gastrointestinal tract: Diarrhea, vomiting and sadness vomiting, abdominal pain, flatulence, indigestion, loss of appetite. Causes serum amylase levels to be elevated and pancreatitis. Hypophosphatemia occurs. A skin rash may also occur. Headache, muscle pain, dizziness, insomnia, weakness, depression, sweating. Increased liver enzymes, hyperglycemia and neutrophil deficiency, increased blood triglyceride levels. Causes renal failure, acute renal failure and proximal tubular effects, including Fanconi's syndrome. Lactic acidosis + severe hepatomegaly and fatty liver , common with treatment with nucleoside reverse transcriptase inhibitors. Note: Patients who see any of the above undesirable effects should immediately notify the doctor for timely intervention to avoid danger. Patients should carefully read the instructions for use of Tenfova before using.
8. Pay attention to precautions when using Tenfova
In the course of treatment with Tenfova, the patient should be careful to note the following:
For pregnant women: Currently, there is no information on the use of Tenofovir disoproxil fumarate for women during pregnancy. pregnancy period. Tenofovir disoproxil fumarate should only be used when the demonstrated benefit outweighs the risk to the fetus. For women of childbearing age: Due to the increased risk of fertility when using the drug for treatment is unknown, but during the use of Tenofovir disoproxil fumarate in women of reproductive age, it is necessary to accompany it. effective methods of contraception. Lactation: Not much is known about whether Tenofovir disoproxil fumarate is excreted in human milk. Therefore, Tenofovir should not be administered to a nursing woman. There is a general recommendation that HIV-infected women should not breastfeed to avoid transmitting HIV to their babies. Take care to keep the medicine out of the reach of children. Note: Tenfova is prescribed by a doctor, patients do not arbitrarily use Tenfova. Taking the medicine exactly as prescribed and the dose will bring more results for the patient.
